8 assets in Kaposi'S Sarcoma

Therapeutic assets addressing Kaposi'S Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Kaposi'S Sarcoma	Fred Hutchinson Cancer Center	P2	B (60)
L19IL2/L19TNF Kaposi'S Sarcoma	Philogen S.p.A.	P2	CCC (53)
cd146/her2 car-t cells Kaposi'S Sarcoma	Essen Biotech	P1/2	CCC (48)
Pembrolizumab Kaposi'S Sarcoma	Memorial Sloan Kettering Cancer Center	P1	CC (47)
mq719 Kaposi'S Sarcoma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Pomalidomide Kaposi'S Sarcoma	National Cancer Institute (NCI)	P1	CC (43)
Adriamycin Kaposi'S Sarcoma	Baxter Healthcare Corporation	P1	NR ()
Cabozantinib Kaposi'S Sarcoma	National Cancer Institute (NCI)	P1	NR ()